Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Semin Cancer Biol. 2023 May 12;93:70–82. doi: 10.1016/j.semcancer.2023.05.003

Table 3.

Ongoing clinical trials involving EVs for the prediction of metastatic progression in cancer patients (data collected from http://clinicaltrials.gov, accessed in Dec 2022).

Clinical Trial Cancer Type Identifier
Contents of circulating extracellular vesicles: biomarkers in colorectal cancer patients CRC NCT04523389
Development of novel imaging and laboratory biomarkers to monitor the liver pre-metastatic niche and guide treatment of colon cancer: a pilot study NCT03432806
Diagnostic and prognostic values of EUS-FNA specimens and circulating exosomal small RNA in patients with pancreatic cancer PDAC NCT04636788
Circulating exosomes as potential prognostic and predictive biomarkers in advanced gastric cancer patients: a prospective observational study (“EXO-PPP Study”) Gastric cancer NCT01779583
Exosomes-derived ncRNAs as biomarkers in cholangiocarcinoma patients Cholangiocarcinoma NCT03102268
Non-coding RNA in the exosome of the epithelia ovarian cancer Epithelia ovarian cancer NCT03738319
A prospective study of predicting prognosis and recurrence of thyroid cancer via new biomarkers, urinary exosomal thyroglobulin and galectin-3 Thyroid cancer NCT03488134
Study of exosomes in monitoring patients with sarcoma (EXOSARC) Sarcoma NCT03800121
A pilot study of circulating exosome RNA as diagnostic and prognostic markers in lung metastases of primary high-grade osteosarcoma Osteosarcoma NCT03108677
Feasibility of exosome analysis in cerebrospinal fluid during the diagnostic workup of metastatic meningitis from breast cancer Breast cancer NCT05286684
Interest of circulating tumor DNA in digestive and gynecologic/breast Cancer Breast cancer/ Digestive cancer/ Gynecologic cancer NCT04530890
Validating the miR Scientific Sentinel platform (Sentinel PCC4 assay) in men undergoing core needle biopsy due to suspicion of prostate cancer for distinguishing between no cancer, low-, intermediate- and high-risk prostate cancer Prostate cancer NCT04100811
Quantification and purification of circulating prostasomes as diagnostic tool for prostate cancer detection NCT03694483
A prospective, randomized blinded, shared decision impact trial of the ExoDx Prostate (IntelliScore), EPI test, in men presenting for initial biopsy. NCT03235687
To investigate the diagnostic accuracy of exosomal microRNA in predicting the aggressiveness of prostate cancer in Chinese patients NCT03911999
Identification and characterization of predictive factors of onset of bone metastases in cancer patients Not specified NCT03895216